Avidity Biosciences (RNA) Equity Ratio (2019 - 2025)
Historic Equity Ratio for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to 0.88.
- Avidity Biosciences' Equity Ratio fell 354.05% to 0.88 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.88, marking a year-over-year decrease of 354.05%. This contributed to the annual value of 0.91 for FY2024, which is 1436.81% up from last year.
- According to the latest figures from Q3 2025, Avidity Biosciences' Equity Ratio is 0.88, which was down 354.05% from 0.87 recorded in Q2 2025.
- In the past 5 years, Avidity Biosciences' Equity Ratio registered a high of 0.93 during Q3 2021, and its lowest value of 0.8 during Q4 2023.
- Moreover, its 5-year median value for Equity Ratio was 0.9 (2022), whereas its average is 0.89.
- Its Equity Ratio has fluctuated over the past 5 years, first tumbled by 1196.19% in 2023, then surged by 1436.81% in 2024.
- Over the past 5 years, Avidity Biosciences' Equity Ratio (Quarter) stood at 0.89 in 2021, then increased by 1.44% to 0.9 in 2022, then dropped by 11.96% to 0.8 in 2023, then rose by 14.37% to 0.91 in 2024, then dropped by 3.0% to 0.88 in 2025.
- Its Equity Ratio stands at 0.88 for Q3 2025, versus 0.87 for Q2 2025 and 0.91 for Q1 2025.